Global clinical stage III and above small molecule oral new crown drugs inventory new drugs VS old drugs-can catch mice is a good cat!

Since the outbreak of the new crown epidemic at the end of 2019, this anti-epidemic war without gunpowder has lasted for nearly two years
.

Small molecule drugs, because they can enter cells, have an unparalleled inhibitory effect on virus replication and cell entry process.
At the same time, oral small molecule drugs do not require high storage conditions, transportation is extremely convenient, and the way of administration is simpler.
Therefore, oral small-molecule new crown drugs have an irreplaceable important role in the war against the new crown epidemic
.

Source: Soochow Securities

In many clinical data studies of small-molecule oral neocorona drugs above stage III, most of them have obvious therapeutic effects compared to placebo, but most of these drugs are new drugs for old drugs.
At the beginning of development and marketing, they are therapeutic Other diseases
.

For example, camostat is a drug used to treat pancreatic inflammation, and the research results show that the new coronavirus SARS-CoV-2 requires the human protease TMPRSS2 to enter the cell, and camostat can inhibit the protease TMPRSS2, so as to achieve the preparation of the new coronavirus The role of replication; the drug nafamostat, which is also used in the treatment of pancreatitis, has been shown to prevent the new coronavirus from entering human cells.
It has previously been listed as the fifth candidate for the treatment of new coronavirus in Japan
.

Image source: Zhihu Virology Notes

It is worth mentioning that Azvudine, developed by the domestic pharmaceutical company Real Bio, is the world’s first dual-target innovative drug targeting HIV reverse transcriptase and the accessory protein Vif, and is a world-leading new generation of domestically pioneered drugs.
Oral AIDS treatment drugs
.

Although it is a new use of old drugs, some old drugs have also played a huge role in the clinical treatment of new crown patients in the early stage of the new crown epidemic
.

Baritinib, jointly developed by Eli Lilly and Incyte, was approved for marketing in the United States in June 2018 for patients with rheumatoid arthritis who have poor efficacy against one or more TNF inhibitors
.

There are also products from domestic pharmaceutical companies that also have good curative effects.
Prokalutamide, a new generation of androgen receptor (AR) antagonist, developed by Pioneer Pharmaceuticals, was originally used in the treatment of prostate cancer and breast cancer in China and the United States.
Phase I-III clinical trials
.

After all, old drugs are not “tailor-made” for the new crown virus.
Major pharmaceutical companies are also actively investing in the research and development of specific drugs for the treatment of new crown patients.
In addition to the recent approval of Merck’s Molnupiravir in the UK, Pfizer’s PF-07321332 also has the latest progress.
In the interim analysis of the Phase 2/3 EPIC-HR study, the risk of hospitalization or death was reduced by 89%
.

Whether it’s an old drug or a new drug, it doesn’t matter whether it’s a black cat or a white cat, it’s a good cat to catch a mouse.

Reference source:

Soochow Securities

Pharmaceutical companies' websites